U.S. patent application number 13/740790 was filed with the patent office on 2014-01-30 for method of inducing negative chemotaxis.
This patent application is currently assigned to CELTAXSYS, INC.. Invention is credited to Erica Brook Goodhew.
Application Number | 20140031321 13/740790 |
Document ID | / |
Family ID | 42099431 |
Filed Date | 2014-01-30 |
United States Patent
Application |
20140031321 |
Kind Code |
A1 |
Goodhew; Erica Brook |
January 30, 2014 |
METHOD OF INDUCING NEGATIVE CHEMOTAXIS
Abstract
The current invention is directed to methods of inducing the
negative chemotaxis of a migratory cell comprising contacting the
cell with a compound selected from the group consisting of
idebenone, benazepril, rolipram, moxonidine, lamivudine,
loxoprofen, terbinafine, synephrine, 6-aminoindazole, and a Vitamin
D analog, or a pharmaceutically acceptable salt of any of
thereof.
Inventors: |
Goodhew; Erica Brook;
(Atlanta, GA) |
Assignee: |
CELTAXSYS, INC.
Atlanta
GA
|
Family ID: |
42099431 |
Appl. No.: |
13/740790 |
Filed: |
January 14, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12576434 |
Oct 9, 2009 |
8377914 |
|
|
13740790 |
|
|
|
|
61104561 |
Oct 10, 2008 |
|
|
|
Current U.S.
Class: |
514/167 ;
514/212.07; 514/269; 514/274; 514/424; 514/570; 514/653; 514/655;
514/690 |
Current CPC
Class: |
A61K 31/592 20130101;
A61K 31/40 20130101; A61K 31/55 20130101; A61P 35/00 20180101; A61K
31/506 20130101; A61K 31/4015 20130101; A61K 31/122 20130101; A61K
31/192 20130101; A61P 29/00 20180101; A61K 31/135 20130101; A61K
31/137 20130101; A61K 31/513 20130101; Y02A 50/411 20180101; A61K
31/593 20130101; A61K 31/59 20130101; Y02A 50/30 20180101 |
Class at
Publication: |
514/167 ;
514/690; 514/212.07; 514/269; 514/274; 514/424; 514/570; 514/653;
514/655 |
International
Class: |
A61K 31/593 20060101
A61K031/593; A61K 31/122 20060101 A61K031/122; A61K 31/55 20060101
A61K031/55; A61K 31/135 20060101 A61K031/135; A61K 31/513 20060101
A61K031/513; A61K 31/4015 20060101 A61K031/4015; A61K 31/192
20060101 A61K031/192; A61K 31/137 20060101 A61K031/137; A61K 31/592
20060101 A61K031/592; A61K 31/506 20060101 A61K031/506 |
Claims
1. A method of inducing negative chemotaxis of a human migratory
cell comprising administering an effective amount of a compound
selected from the group consisting of idebenone, benazepril,
rolipram, moxonidine, lamivudine, loxoprofen, terbinafine,
synephrine, 6-aminoindazole and a Vitamin D analog, or a
pharmaceutically acceptable salt of any of thereof.
2. The method of claim 1, wherein the human migratory cell is an
immune cell.
3. The method of claim 2, wherein the immune cell is selected from
the group consisting of lymphocytes, monocytes, neutrophils,
eosinophils, and mast cells.
4. The method of claim 3, wherein the immune cell is a
neutrophil.
5. The method of claim 3, wherein the immune cell is an
eosinophil.
6. The method of claim 1, wherein the compound is idebenone.
7. The method of claim 1, wherein the compound is benazepril.
8. The method of claim 7, wherein the compound is benazepril
hydrochloride.
9. The method of claim 1, wherein the compound is rolipram.
10. The method of claim 1, wherein the compound is moxonidine.
11. The method of claim 10, wherein the compound is moxonidine
hydrochloride.
12. The method of claim 1, wherein the compound is lamivudine.
13. The method of claim 1, wherein the compound is a Vitamin D
analog.
14. The method of claim 13, wherein the Vitamin D analog is
selected from the group consisting of calcitriol, calcipotriol,
ergocalciferol and cholecalciferol.
15. The method of claim 14, wherein the Vitamin D analog is
calcitriol.
16. The method of claim 1, wherein the compound is loxoprofen.
17. The method of claim 16, wherein the compound is loxoprofen
sodium.
18. The method of claim 1, wherein the compound is terbinafine.
19. The method of claim 18, wherein the compound is terbinafine
hydrochloride.
20. The method of claim 1, wherein the compound is Synephrine.
21. The method of claim 1, wherein the compound is
6-aminoindazole.
22. The method of claim 1, wherein chemotaxis toward a site of
inflammation is inhibited.
23. The method of claim 1, wherein chemotaxis toward a medical
implant is inhibited.
24. The method of claim 1, wherein chemotaxis toward a site of
angiogenesis is inhibited.
25. A method of inhibiting the chemotactic induction of an immune
cell in a patient in need thereof comprising administering to said
patient a therapeutically effective amount of a compound selected
from the group consisting of idebenone, benazepril, rolipram,
moxonidine, lamivudine, loxoprofen, terbinafine, synephrine,
6-aminoindazole and a Vitamin D analog, or a pharmaceutically
acceptable salt of any of thereof.
26. The method of claim 25, wherein the patient is suffering from
an inflammatory condition.
27. The method of claim 25, wherein the compound is administered
locally to the site of inflammation.
28. The method of claim 26, wherein the inflammatory condition is
injection site reaction.
29. The method of claim 25, wherein the patient is suffering from
cancer or a tumor and angiogenesis is inhibited.
30. The method of claim 25, wherein chemotactic induction of an
immune cell toward a medical implant is inhibited.
31. The method of claim 30, wherein the compound is administered by
coating a surface of the medical implant.
32. The method of claim 30, wherein the compound is administered
locally at the site of the medical implant.
33. The method of claim 25, wherein chemotactic induction of an
immune cell toward a transplant or graft is inhibited.
Description
RELATED APPLICATION
[0001] This application is a continuation of U.S. application Ser.
No. 12/576,434, filed Oct. 9, 2009, which claims the benefit of
U.S. Provisional Application No. 61/104,561, filed Oct. 10, 2008.
The entire teachings of the above application are incorporated
herein by reference.
BACKGROUND OF THE INVENTION
[0002] Chemotaxis, or the oriented movement of a cell in response
to a chemical agent, is a complex and highly integrated process.
The movement can be positive (toward) or negative (away) from a
chemical gradient. Movement toward an agent or stimulus is termed
positive chemotaxis (i.e., the agent or stimulus is chemoattractive
for the cell), while movement away from an agent or stimulus is
termed negative chemotaxis (i.e., the agent or stimulus is
chemorepulsive for the cell). It is believed that for both
prokaryotes and eukaryotes, cells undergoing chemotaxis sense a
change in agent concentration and, thereby, move in response to the
concentration gradient. Chemoattraction (CA) and chemorepulsion
(CR) are therefore properties of the agent or stimulus, while
chemotaxis is a property of cells.
[0003] Within the immune system, chemotaxis is often driven by a
class of biological agents, known as chemokines (or chemotactic
cytokines). Once triggered, chemotaxis plays an important role in
various physiologic and cellular processes including tissue
organization, organogenesis' homeostasis, embryonic morphogenesis
tissue repair and regeneration and disease progression in cancer,
mental retardation, atherosclerosis, and arthritis. Compounds that
affect chemotaxis (either induce positive or negative chemotaxis)
would therefore be useful in modulating these and other biologic
processes. Compounds that induce negative chemotaxis have in fact
been described as useful in treating inflammation, in inhibiting
tumor metastasis and in contraception.
[0004] It would therefore be advantageous to identify additional
compounds that induce negative chemotaxis.
SUMMARY OF THE INVENTION
[0005] The present invention provides methods of inducing the
negative chemotaxis of a migratory cell comprising contacting the
cell with a compound selected from the group selected from the
group consisting of idebenone, benazepril, rolipram, moxonidine,
lamivudine, loxoprofen, terbinafine, synephrine, 6-aminoindazole,
and a Vitamin D analog, or pharmaceutically acceptable salts
thereof.
[0006] In another embodiment, the invention is a method of inducing
negative chemotaxis of a human immune cell comprising administering
a compound selected from the group consisting of idebenone,
benazepril, rolipram, moxonidine, lamivudine, loxoprofen,
terbinafine, synephrine, 6-aminoindazole and a Vitamin D analog, or
pharmaceutically acceptable salts thereof.
[0007] In yet another embodiment, the invention is a method of
treating a condition mediated by migration of a human migratory
cell toward a chemotactic site comprising administering to said
patient a compound selected from the group consisting of idebenone,
benazepril, rolipram, moxonidine, lamivudine, loxoprofen,
terbinafine, synephrine, 6-aminoindazole, and a Vitamin D analog,
or pharmaceutically acceptable salts thereof, wherein the compound
is administered in an amount effective to inhibit migration of the
cell toward the chemotactic site.
[0008] In a further embodiment, the invention is a method of
treating a patient suffering from an inflammatory condition
comprising administering to said patient a compound selected from
the group consisting of idebenone, benazepril, rolipram,
moxonidine, lamivudine, loxoprofen, terbinafine, synephrine,
6-aminoindazole, and a Vitamin D analog, or pharmaceutically
acceptable salts thereof, wherein the compound is administered in a
therapeutically effective amount.
[0009] In an additional embodiment, the invention is a method of
inhibiting angiogenesis comprising administering to said patient a
compound selected from the group consisting of idebenone,
benazepril, rolipram, moxonidine, lamivudine, loxoprofen,
terbinafine, synephrine, 6-aminoindazole, and a Vitamin D analog,
or pharmaceutically acceptable salts thereof, wherein the compound
is administered in a therapeutically effective amount.
[0010] In yet another embodiment, the invention is a method of
contraception comprising in a patient in need thereof comprising
administering a compound selected from the group consisting of
idebenone, benazepril, rolipram, moxonidine, lamivudine,
loxoprofen, terbinafine, synephrine, 6-aminoindazole, and a Vitamin
D analog, or pharmaceutically acceptable salts thereof in an amount
effective to inhibit migration of germ cells in the subject.
[0011] In some embodiments, the compound is a Vitamin D analog. In
other embodiments, the Vitamin D analog is selected from the group
consisting of calcitriol, calcipotriene, ergocalciferol and
cholecalciferol. In a further embodiment, the Vitamin D analog is
calcitriol.
[0012] These and other aspects of the invention, as well as various
advantages and utilities, will be more apparent with reference to
the drawings and the detailed description of the embodiments of the
invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. 1A is a bar graph showing fold induction (over media)
of chemorepulsion (right) and chemoattraction (left) of neutrophils
treated with 0.102, 1.02, 10.2 and 102 uM idebenone.
[0014] FIGS. 1B and 1C are bar graphs showing fold induction (over
media) of chemorepulsion (right) and chemoattraction (left) of
neutrophils treated with 3.8, 11.3, 34 and 102 uM idebenone.
[0015] FIGS. 2A-C are bar graphs showing fold induction (over
media) of chemorepulsion of neutrophils treated with 0.092, 0.92,
9.2 and 92 uM benazepril hydrochloride.
[0016] FIG. 3A is a bar graph showing fold induction (over media)
of chemorepulsion of neutrophils treated with 0.1, 1, 10 and 100 uM
rolipram.
[0017] FIG. 3B is a bar graph showing fold induction (over media)
of chemorepulsion of neutrophils treated with 0.01, 0.1, 1 and 10
uM rolipram.
[0018] FIG. 4A is a bar graph showing fold induction (over media)
of chemorepulsion of neutrophils treated with 0.092, 0.92, 9.2 and
92 uM moxonidine hydrochloride.
[0019] FIG. 4B is a bar graph showing fold induction (over media)
of chemorepulsion of neutrophils treated with 0.0092, 0.092, 0.92
and 9.2 moxonidine hydrochloride.
[0020] FIGS. 5A-B are bar graphs showing fold induction (over
media) of chemorepulsion of neutrophils treated with 0.099, 0.99,
9.9 and 99 uM lamivudine.
[0021] FIG. 6A is a bar graph showing fold induction (over media)
of chemorepulsion (right) and chemoattraction (left) of neutrophils
treated with 0.1, 1, 10 and 100 uM calcitriol.
[0022] FIGS. 6B-C are bar graphs showing fold induction (over
media) of chemorepulsion (right) and chemoattraction (left) of
neutrophils treated with 3.7, 11.1, 33.3 and 100 uM calcitriol.
[0023] FIGS. 7A and B are bar graphs showing fold induction (over
media) of chemorepulsion of neutrophils treated with 0.089, 0.89,
8.9 and 89 uM terbinafine hydrochloride.
[0024] FIG. 7C is a bar graph showing fold induction (over media)
of chemorepulsion (right) and chemoattraction (left) of neutrophils
treated with 0.089, 0.89, 8.9 and 89 uM terbinafine
hydrochloride.
[0025] FIG. 8A is a bar graph showing fold induction (over media)
of chemorepulsion of neutrophils treated with 0.1, 1, 10 and 100 uM
synephrine.
[0026] FIG. 8B is a bar graph showing fold induction (over media)
of chemorepulsion of neuthrophils treated with 0.01, 0.1, 1 and 10
uM synephrine.
[0027] FIG. 9A is a bar graph showing fold induction (over media)
of chemorepulsion of neutrophils treated with 0.1, 1, 10 and 100 uM
6-aminoindazole.
[0028] FIG. 9B is a bar graph showing fold induction (over media)
of chemorepulsion of neutrophils treated with 0.01, 0.1, 1 and 10
uM 6-aminoindazole.
[0029] FIG. 10A is a bar graph showing fold induction (over media)
of chemorepulsion of neutrophils treated with 0.091, 0.91, 9.1 and
91 uM loxoprofen sodium.
[0030] FIG. 10B is a bar graph showing fold induction (over media)
of chemorepulsion of neutrophils treated with 0.0091, 0.091, 0.91
and 9.1 uM loxoprofen sodium.
[0031] FIG. 11 is a plot of fold induction (over media) of
chemorepulsion of neutrophils treated with 3.7, 11.1, 33.3 and 100
uM of calcipotriene.
[0032] FIG. 12 is a plot of fold induction (over media) of
chemorepulsion of neutrophils treated with 3.7, 11.1, 33.3 and 100
uM of Vitamin D2.
[0033] FIG. 13 is a plot of fold induction (over media) of
chemorepulsion of neutrophils treated with 3.7, 11.1, 33.3 and 100
uM of Vitamin D3.
[0034] FIG. 14 is a bar graph showing fold induction (over media)
of chemorepulsion of neutrophils treated with 0.101, 1.01, 10.1 and
101 uM calcipotriol.
DETAILED DESCRIPTION OF THE INVENTION
[0035] A description of the embodiments of the invention
follows.
[0036] As used herein, "a" or "an" are taken to mean one or more
unless otherwise specified.
[0037] The present invention is based on the surprising discovery
that the compounds idebenone, benazepril, rolipram, moxonidine,
lamivudine, calcitriol, calcipotriene, ergocalciferol,
cholecalciferol, loxoprofen, terbinafine, synephrine and
6-aminoindazole and pharmaceutically acceptable salts thereof
induce negative chemotaxis of human migratory cell. For example, as
shown in Example 1, neutrophils contacted with 102 uM idebenone
showed between about 3 and 8-fold greater induction of chemotaxis
than that in response to media.
[0038] Idebenone
(6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone) is a
synthetic analog of the antioxidant Coenzyme Q10. Idebenone has
been described as promoting nerve growth factor (NGF) in the brain
(Nitta et al. 1993. Neurosci Lett. 163(2):219-22). Idebenone has
been described as useful for the treatment of Alzheimer's disease
(Senin et al., (1992). Arch Gerontol Geriatr. 1992
November-December; 15(3):249-60; U.S. Pat. No. 5,059,627) and
Friedrich's ataxia (Tonon et al. (2008). Expert Opin Pharmacother.
2008 September; 9(13):2327-37). Idebenone has the chemical
structure shown below:
##STR00001##
[0039] Benazepril is an angiotensin-converting enzyme (ACE)
inhibitor and is marketed under the trade name LOTENSIN.RTM. for
the treatment hypertension (Gomez et al. (1991). Clin Cardiol. 1991
August; 14(8 Suppl 4):IV22-7. Kuhn et al. AACN Clin Issues Crit
Care Nurs. 1992 May; 3(2):461-71). Benazepril has also been
described as useful in the treatment of congestive heart failure
(Kuhn et al.) and chronic renal insufficiency (Maschio et al.
(1996). N Engl J Med. 1996 Apr. 11; 334(15):939-45). Benazepril has
the following chemical structure:
##STR00002##
[0040] Rolipram
(4-(3-cyclopentyloxy-4-methoxy-phenyl)pyrrolidin-2-one) is a
phosphodiesterase-4 (PDE-4) inhibitor and has been shown to inhibit
the production of tumor necrosis factor (TNF) alpha (Prabhakar et
al. (1994). Int J Immunopharmacol. 1994 October; 16(10):805-16).
Rolipram has been described as useful as an anti-inflammatory agent
(Dyke (2002) Expert Opin Investig Drugs. 11(1):1-13) and as an
antidepressant (Zhu et al. (2001). CNS Drug Rev. Winter;
7(4):387-98). Rolipram has the chemical structure shown below:
##STR00003##
[0041] Moxonidine is a centrally acting anti-hypertensive agent
(Chrisp et al. (1992). Drugs, 44(6):993-1012) and acts as a
selective agonist of the imidazoline receptor subtype 1 (Ernsberger
et al. (1994). Cardiovasc Drugs Ther. Suppl, 1:27-41). Moxonidine
has the following chemical structure:
##STR00004##
[0042] Lamivudine
(4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one-
) is a nucleoside analog reverse transcriptase inhibitor.
Lamivudine has been used in the treatment of hepatitis B (Rousssos
et al. (2008). Acta Gastroenterol Belg. 71(1):30-2) and HIV (Perry
et al. (1997), 53(4):657-80). Lamivudine is marketed under the
trade names ZEFFIX.RTM. and EPIVIR.RTM. and has the chemical
structure shown below:
##STR00005##
[0043] Loxoprofen is a non-steroidal anti-inflammatory drug that
inhibits cyclooxygenase (Noguchi et al. (2005) Biol Pharm Bull,
28(11): 2075-79). Loxoprofen sodium has the chemical structure
shown below:
##STR00006##
[0044] Terbinafine
(N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine)
is a synthetic allylamine antifungal agent that inhibits ergosterol
synthesis (Leyden (1998). J Am Acad Dermatol, 1998 May; 38(5 Pt
3):S42-7). Terbinafine hydrochloride is marketed under the trade
names LAMISIL.RTM. and TERBISIL.RTM. for the treatment of
onychomycosis and other fungal infections (Balfour et al. (2002)
Drugs. 1992 February; 43(2):259-84). Terbinafine has the chemical
structure shown below:
##STR00007##
[0045] Synephrine is derived from Citrus aurantium and has been
described as having lipolytic effects on human fat cells
(Fugh-Berman et al. (2004). Exp Biol Med (Maywood). 229(8):698-704.
Synephrine has the following chemical structure:
##STR00008##
[0046] 6-aminoindazole has been shown to suppress gastric acid
secretion (Pinelli et al. (1989). Arzneimittelforschung. 1989
March; 39(3):361-5). 6-aminoindazole has the chemical structure
shown below:
##STR00009##
[0047] Vitamin D is a group prohormones with several active
metabolites that act as hormones. Vitamin D includes
cholecalciferol (Vitamin D3) and ergocalciferol (Vitamin D2).
7-dehydroxycholesterol is found in the skin and when exposed to
sunlight is converted to cholecalciferol. Ergosterol, found in
plants, is the provitamin for Vitamin D2 (ergocalciferol). The
primary active metabolite of Vitamin D is calcitriol
(1,25-dihydroxyvitamin D). The term "Vitamin D analog" encompasses
Vitamin D, Vitamin D metabolites and synthetic derivatives thereof
(Goodman and Gilman, The Pharmacologic Basis of Therapeutics).
Synthetic derivatives of Vitamin D include, for example,
dihydrotachysterol, 25-hydroxydihydrotachysterol,
1.alpha.-hydroxycholecalciferol, calcipotriol and 22-oxacalcitriol.
Vitamin D analogs include, but are not limited to, cholecalciferol,
ergosterol, calcitriol, 25(OH)D3, dihydrotachysterol,
25-hydroxydihydrotachysterol, 1a-hydroxycholecalciferol,
25-hydroxycholecalciferol, calcipotriol, 22-oxacalcitriol,
ergocalciferol, 1.alpha.-25-dihydroxyergocalciferol,
22,23-dihydroergocalciferol, 1,24,25-trihydroxycholecalciferol,
previtamin D3, tacalciol, isovitamin D3, dihydrotachysterol3,
(1S)-hydroxycalciol, (24R)-hydroxycalcidiol, 25-fluorocalciol,
ercalcidiol, ertacalciol, (5E)-isocalciol, 22,23-dihydroercalciol,
(24S)-methylcalciol, (5E)-(10S)-10,19-dihydroercalciol,
(24S)-ethylcalciol, 22-dihydroergocalciferol, calcifidiol and
(22E)-(24R)-ethyl-22,23-didehydrocalciol. Other Vitamin D analogs,
have been described, for example in U.S. Pat. No. 4,851,401
(cyclopentano-vitamin D analogs), U.S. Pat. No. 5,120,722
(trihydroxycalciferol derivatives), U.S. Pat. No. 5,446,035
(20-methyl substituted vitamin D), U.S. Pat. No. 5,411,949
(23-oxa-derivatives), U.S. Pat. No. 5,237,110 (19-nor-vitamin D
compounds), U.S. Pat. No. 4,857,518 (hydroxylated 24-homo-vitamin D
derivatives). Other Vitamin D analogs are taught in U.S. Pat. Nos.
4,804,502; 4,866,048; 5,145,846 5,374,629; 5,403,940; 5,446,034;
and 5,447,924, 7,115,758, 7,312,249, 7,241,752, 7,361,664.
Calcitriol analogs include, but are not limited to, calcipotriene,
Vitamin D2, Vitamin D3, 1.alpha.-OH-Vitamin D3, 1.alpha.-OH-Vitamin
D2, calcifediol, Vitamin D4, 1.alpha.-25-dihydroxyvitamin D3,
19-nor-1,25-dihydroxyvitamin D2,
24-homo-22-dehydro-22E-1.alpha.-25-dihydroxyvitamin D3,
1,25-dihydroxy-24(E)-dehydro-24-homo-vitamin D.sub.3, and
19-nor-1,25-dihydroxy-21-epi-vitamin D3.
[0048] Calcitriol increases absorption of calcium and phosphate in
the gastrointestinal tract (Favus et al. (1985). Am J. Physiol.,
248(2 Pt 1):G147-57). Calcitriol is marketed as ROCALTROL.RTM.,
CALCIJEX.RTM. and DECOSOTRIOL.RTM. and has the following chemical
structure:
##STR00010##
[0049] The term "chemorepellant Vitamin D analog" refers to a
Vitamin D analog that is capable of inducing negative chemotaxis of
a human migratory cell. In certain aspects, the chemorepellant
Vitamin D analog is selected from the group consisting of
calcitriol, calcipotriene, ergocalciferol and cholecalciferol.
[0050] Pharmaceutically acceptable salts of the compounds described
above are non-toxic, inorganic and organic acid and base addition
salts. Exemplary acid-addition salts include those derived from
inorganic acids such as hydrochloric acid, hydrobromic acid,
hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and
nitric acid, and those derived from organic acids such as
p-toluenesulfonic acid, salicylic acid, methanesulfonic acid,
oxalic acid, succinic acid, citric acid, malic acid, lactic acid,
fumaric acid, trifluoro acetic acid and the like. Sample
base-addition salts include those derived from ammonium, potassium,
sodium and, quaternary ammonium hydroxides, such as, for example,
tetramethylammonium hydroxide. Chemical modification of a
pharmaceutical compound (i.e. drug) into a salt is a technique well
known to pharmaceutical chemists to obtain improved physical and
chemical stability, hygroscopicity, flowability and solubility of
compounds. See, e.g., Ansel et al., Pharmaceutical Dosage Forms and
Drug Delivery Systems (6th Ed. 1995) at pp. 196 and 1456-1457.
[0051] As used herein, "migratory cells" are those cells which are
capable of movement from one place to another in response to a
stimulus. Human migratory cells include those involved in the
processes of cancer, immunity, angiogenesis or inflammation and
also include those identified to play a role in other disease
states or conditions. Migratory cells include, but are not limited
to, immune cells, hematopoietic cells, neural cells, epithelial
cells, mesenchymal cells, stem cells, germ cells and cells involved
in angiogenesis.
[0052] Immune cells include, but are not limited to, monocytes,
Natural Killer (NK) cells, dendritic cells (which could be immature
or mature), subsets of dendritic cells including myeloid,
plasmacytoid (also called lymphoid) or Langerhans; macrophages such
as histiocytes, Kupffer's cells, alveolar macrophages or peritoneal
macrophages; neutrophils, eosinphils, mast cells, basophils; B
cells including plasma B cells, memory B cells, B-1 cells, B-2
cells; CD45RO (naive T), CD45RA (memory T); CD4 Helper T Cells
including Th1, Th2 and Tr1/Th3; CD8 Cytotoxic T Cells, Regulatory T
Cells and Gamma Delta T Cells.
[0053] Hematopoietic cells include, but are not limited to,
pluripotent stem cells, multipotent progenitor cells and/or
progenitor cells committed to specific hematopoietic lineages. The
progenitor cells committed to specific hematopoietic lineages can
be of T cell lineage, B cell lineage, dendritic cell lineage,
neutrophil lineage, Langerhans cell lineage and/or lymphoid
tissue-specific macrophage cell lineage. The hematopoietic cells
can be derived from a tissue such as bone marrow, peripheral blood
(including mobilized peripheral blood), umbilical cord blood,
placental blood, fetal liver, embryonic cells (including embryonic
stem cells), aortal-gonadal-mesonephros derived cells, and lymphoid
soft tissue. Lymphoid soft tissue includes the thymus, spleen,
liver, lymph node, skin, tonsil and Peyer's patches. In other
embodiments, hematopoietic cells can be derived from in vitro
cultures of any of the foregoing cells, and in particular in vitro
cultures of progenitor cells.
[0054] Neural cells are cells of neural origin and include neurons
and glia and/or cells of both central and peripheral nervous
tissue.
[0055] Epithelial cells include cells of a tissue that covers and
lines the free surfaces of the body. Such epithelial tissue
includes cells of the skin and sensory organs, as well as the
specialized cells lining the blood vessels, gastrointestinal tract,
air passages, lungs, ducts of the kidneys and endocrine organs.
[0056] Mesenchymal cells include, but are not limited to, cells
that express typical fibroblast markers such as collagen, vimentin
and fibronectin.
[0057] Cells involved in angiogenesis are cells that are involved
in blood vessel formation and include cells of endothelial origin
and cells of mesenchymal origin.
[0058] Germ cells are cells specialized to produce haploid
gametes.
[0059] In certain embodiment, the human migratory cell is an immune
cell. In other embodiments, the immune cell is selected from the
group consisting of lymphocytes, monocytes, neutrophils,
eosinophils and mast cells. In a further embodiment, the immune
cell is a neutrophil or an eosinophil.
[0060] As used herein, the terms "contact" or "contacting" means
the act of touching or bringing together two entities or things in
such proximity as will allow an influence of at least one on the
other. The definition, while inclusive of physical contact is not
so limited.
[0061] As used herein, a "chemorepellant" is an agent or stimulus
that induces, elicits or triggers negative chemotaxis of a
migratory cell. A "chemoattractant" is an agent or stimulus that
induces, elicits or triggers positive chemotaxis (movement towards
an agent or stimulus) by a migratory cell. Compounds selected from
the group consisting of idebenone, benazepril, rolipram,
moxonidine, lamivudine, calcitriol, loxoprofen, terbinafine,
synephrine and 6-aminoindazole or pharmaceutically acceptable salts
thereof have been discovered to be chemorepellants. As used herein
the terms "induce," "elicit," and "trigger," when referring to the
activity of a chemorepellant or chemoattractant with respect to
negative or positive chemotaxis, carry the same meaning. The term
"agent" refers generally to any chemical compound or biologic.
[0062] Based on their ability to induce negative chemotaxis,
compounds selected from the group consisting of idebenone,
benazepril, rolipram, moxonidine, lamivudine, loxoprofen,
terbinafine, synephrine, 6-aminoindazole and Vitamin D analogs, or
pharmaceutically acceptable salts thereof are useful inhibiting the
induction of chemotaxis of migratory cells toward a chemotactic
site. As used herein, a "chemotactic site" is a site that induces
positive chemotaxis of migratory cells. Chemotactic sites include
sites of inflammation, medical implants, transplants and
angiogenesis.
[0063] Compounds selected from the group consisting of idebenone,
benazepril, rolipram, moxonidine, lamivudine, loxoprofen,
terbinafine, synephrine, 6-aminoindazole, Vitamin D analogs, or
pharmaceutically acceptable salts thereof are useful for inhibiting
the induction of chemotaxis of migratory cells toward a site of
inflammation. Inhibiting migratory cell chemotaxis toward a site of
inflammation can result in a reduction or amelioration of an
inflammatory response in situations such as bacterial infection,
tissue injury-induced inflammation (e.g., ischemia-reperfusion
injury), complement-induced inflammation, oxidative stress (e.g.,
hemodialysis), immune complex-induced inflammation (e.g.,
antibody-mediated glomerunephritis), cytokine-induced inflammation
(e.g., rheumatoid arthritis), antineutrophil cytoplasmic antibodies
and vasculitis (e.g, autoimmunity against neutrophil components),
genetic disorders of neutrophil regulations (e.g., hereditary
periodic fever syndromes), implant related inflammation, and cystic
fibrosis.
[0064] In certain embodiments, the invention is a method of
treating an inflammatory condition in a patient suffering therefrom
comprising administering to said patient a compound selected from
the group consisting of idebenone, benazepril, rolipram,
moxonidine, lamivudine, loxoprofen, terbinafine, synephrine,
6-aminoindazole, Vitamin D analogs, or pharmaceutically acceptable
salts thereof in a therapeutically effective amount. Inflammatory
conditions include, but are not limited to, appendicitis, peptic,
gastric or duodenal ulcers, peritonitis, pancreatitis, acute or
ischemic colitis, diverticulitis, epiglottitis, achalasia,
cholangitis, cholecystitis, hepatitis, inflammatory bowel disease
(including, for example, Crohn's disease and ulcerative colitis),
enteritis, Whipple's disease, asthma, chronic obstructive pulmonary
disease, acute lung injury, ileus (including, for example,
post-operative ileus), allergy, anaphylactic shock, immune complex
disease, organ ischemia, reperfusion injury, organ necrosis, hay
fever, sepsis, septicemia, endotoxic shock, cachexia, hyperpyrexia,
eosinophilic granuloma, granulomatosis, sarcoidosis, septic
abortion, epididymitis, vaginitis, prostatitis, urethritis,
bronchitis, emphysema, rhinitis, cystic fibrosis, pneumonitis,
pneumoultramicroscopic silicovolcanoconiosis, alvealitis,
bronchiolitis, pharyngitis, pleurisy, sinusitis, influenza,
respiratory syncytial virus, herpes, disseminated bacteremia,
Dengue fever, candidiasis, malaria, filariasis, amebiasis, hydatid
cysts, burns, dermatitis, dermatomyositis, urticaria, acne,
vasulitis, angiitis, endocarditis, arteritis, atherosclerosis,
thrombophlebitis, pericarditis, myocarditis, myocardial ischemia,
periarteritis nodosa, rheumatic fever, Alzheimer's disease, celiac
disease, congestive heart failure, adult respiratory distress
syndrome, meningitis, encephalitis, multiple sclerosis, cerebral
infarction, cerebral embolism, Guillame-Barre syndrome, neuritis,
neuralgia, uveitis, arthritides, arthralgias, osteomyelitis,
fasciitis, Paget's disease, gout, periodontal disease, rheumatoid
arthritis, synovitis, myasthenia gravis, thryoiditis, systemic
lupus erythematosus, Goodpasture's syndrome, Behcet's syndrome,
allograft rejection, graft-versus-host disease, Type I diabetes,
ankylosing spondylitis, Berger's disease, Type II diabetes,
Retier's syndrome, Hodgkins disease and injection site
reaction.
[0065] Injection site reaction is a term generally used to describe
inflammation in and around a site of injection. Injection site
reaction has been observed with the injection of numerous
pharmaceutical agents including, but not limited, chemotherapeutic
drugs, immunomodulator drugs, and vaccines. The present invention
encompasses a method for the treatment or reduction of injection
site reaction comprising administration of a compound selected from
the group consisting of idebenone, benazepril, rolipram,
moxonidine, lamivudine, loxoprofen, terbinafine, synephrine,
6-aminoindazole, Vitamin D analogs, or pharmaceutically acceptable
salts thereof. A compound selected from the group consisting of
idebenone, benazepril, rolipram, moxonidine, lamivudine,
loxoprofen, terbinafine, synephrine, 6-aminoindazole, Vitamin D
analogs, or pharmaceutically acceptable salts thereof can, for
example, be administered before, during or after injection. In some
embodiments, the compound selected from the group consisting of
idebenone, benazepril, rolipram, moxonidine, lamivudine,
loxoprofen, terbinafine, synephrine, 6-aminoindazole, Vitamin D
analogs, or pharmaceutically acceptable salts thereof can be
administered topically at the site of the injection.
[0066] In another embodiment, the invention is a method of
inhibiting positive chemotaxis toward a medical implant. The
medical implant can be contacted or coated with a compound selected
from idebenone, benazepril, rolipram, moxonidine, lamivudine,
loxoprofen, terbinafine, synephrine, 6-aminoindazole, Vitamin D
analogs, or pharmaceutically acceptable salts thereof in amount
sufficient to induce negative chemotaxis of an immune cell. The
compounds can also be administered locally at the site of the
medical implant. A medical implant is defined as a device or entity
implanted into a surgically or naturally formed cavity of the body.
Medical implants include, but are not limited to, stents,
pacemakers, pacemaker leads, defibrillators, drug delivery devices,
sensors, pumps, embolization coils, sutures, electrodes,
cardiovascular implants, arterial stents, heart valves, orthopedic
implants, dental implants, bone screws, plates, catheters,
cannulas, plugs, fillers, constrictors, sheets, bone anchors,
plates, rods, seeds, tubes, or portions thereof. In addition to the
compound selected from the group consisting of idebenone,
benazepril, rolipram, moxonidine, lamivudine, loxoprofen,
terbinafine, synephrine, 6-aminoindazole, and Vitamin D analogs, or
pharmaceutically acceptable salts thereof, the medical implant can
be coated with a cell-growth potentiating agent, an anti-infective
agent and/or an anti-inflammatory agent.
[0067] In yet another embodiment, the invention is a method of
inhibiting positive chemotaxis toward an organ transplant or tissue
graft. Organ transplants and tissue grants include, but are not
limited to, renal, pancreatic, hepatic, lymphoid and cardiac grafts
and organs. Lymphoid grafts include a splenic graft, a lymph node
derived graft, a Peyer's patch derived graft, a thymic graft and a
bone marrow derived graft. In an additional embodiment, the
invention is a method of treating a patient suffering from
transplant or graft rejection comprising administering a compound
selected from idebenone, benazepril, rolipram, moxonidine,
lamivudine, loxoprofen, terbinafine, synephrine, 6-aminoindazole,
and a Vitamin D analog, or pharmaceutically acceptable salts
thereof.
[0068] As discussed above, the compounds described above can be
used to inhibit chemotaxis toward a site of angiogenesis. A site of
angiogenesis is a site where blood vessels are being formed. In one
embodiment, the invention is a method of inducing negative
chemotaxis of endothelial cells toward a site of angiogenesis. The
invention also encompasses a method of inhibiting angiogenesis in a
patient in need thereof comprising administering a compound
selected from the group consisting of idebenone, benazepril,
rolipram, moxonidine, lamivudine, loxoprofen, terbinafine,
synephrine, 6-aminoindazole and a Vitamin D analog, or
pharmaceutically acceptable salts thereof in a therapeutically
effective amount. In a further embodiment, the invention is a
method of treating cancer or a tumor comprising administering a
compound selected from idebenone, benazepril, rolipram, moxonidine,
lamivudine, loxoprofen, terbinafine, synephrine, 6-aminoindazole,
and a Vitamin D analog, or pharmaceutically acceptable salts
thereof in an amount effective to inhibit angiogenesis. According
to another aspect of the invention, a method of inhibiting
endothelial cell migration to a tumor site in a subject is
provided. The method involves locally administering to or
contacting an area surrounding a tumor site in need of such
treatment a compound selected from the group consisting of
idebenone, benazepril, rolipram, moxonidine, lamivudine,
loxoprofen, terbinafine, synephrine, 6-aminoindazole and a Vitamin
D analog, or pharmaceutically acceptable salts thereof in an amount
effective to inhibit endothelial cell migration into the tumor site
in the subject.
[0069] Exemplary cancers and tumors that can be treated according
to the methods of the invention include, for example, biliary tract
cancer; brain cancer including glioblastomas and medulloblastomas;
breast cancer; cervical cancer; choriocarcinoma; colon cancer;
endometrial cancer; esophageal cancer, gastric cancer;
hematological neoplasms, including acute lymphocytic and
myelogenous leukemia; multiple myeloma; AIDS associated leukemias
and adult T-cell leukemia lymphoma; intraepithelial neoplasms,
including Bowen's disease and Paget's disease; liver cancer
(hepatocarcinoma); lung cancer; lymphomas, including Hodgkin's
disease and lymphocytic lymphomas; neuroblastomas; oral cancer,
including squamous cell carcinoma; ovarian cancer, including those
arising from epithelial cells, stromal cells, germ cells and
mesenchymal cells; pancreas cancer; prostate cancer; rectal cancer;
sarcomas, including leiomyosarcoma, rhabdomyosarcoma, liposarcoma,
fibrosarcoma and osteosarcoma; skin cancer, including melanoma,
Kaposi's sarcoma, basocellular cancer and squamous cell cancer;
testicular cancer, including germinal tumors (seminoma,
non-seminoma [teratomas, choriocarcinomas]), stromal tumors and
germ cell tumors; thyroid cancer, including thyroid adenocarcinoma
and medullar carcinoma; and renal cancer including adenocarcinoma
and Wilms tumor.
[0070] The invention also encompasses a method of contraception in
a patient in need thereof comprising administering a compound
selected from idebenone, benazepril, rolipram, moxonidine,
lamivudine, loxoprofen, terbinafine, synephrine, 6-aminoindazole
and a Vitamin D analog, or pharmaceutically acceptable salts
thereof in an amount effective to inhibit migration of germ cells
in the subject. According to another aspect of the invention, a
method of treating infertililty and premature labor is provided.
The method comprises administering a compound described above in an
amount effective to inhibit immune cells from migrating close to a
germ cell in the subject.
[0071] The treatment methods disclosed herein involve
administering, either locally or systemically, to a selected site
in a subject in need of such a treatment the compound selected from
idebenone, benazepril, rolipram, moxonidine, lamivudine,
loxoprofen, terbinafine, synephrine, 6-aminoindazole and a Vitamin
D analog, or pharmaceutically acceptable salts thereof in an amount
effective to induce negative chemotaxis of a human migratory cell.
As used herein, a "therapeutically effective amount" is an amount
sufficient to induce negative migration of a migratory cell and/or
ameliorate a disease or condition of a patient or achieve a desired
outcome. For example, a "therapeutically effective amount" in
reference to the treatment of an inflammatory condition encompasses
an amount sufficient to induce negative chemotaxis of an immune
cell and/or ameliorate a symptom of the inflammatory condition.
[0072] In certain embodiments, the compound selected from
idebenone, benazepril, rolipram, moxonidine, lamivudine,
loxoprofen, terbinafine, synephrine, 6-aminoindazole, and a Vitamin
D analog, or pharmaceutically acceptable salts thereof can be
co-administered with a second agent (e.g., another chemoattractant
or with any drug or agent which is not itself a chemoattractant).
Co-administered agents, compounds, chemoattractants or therapeutics
need not be administered at exactly the same time. In certain
embodiments, however, the compound selected from idebenone,
benazepril, rolipram, moxonidine, lamivudine, loxoprofen,
terbinafine, synephrine, 6-aminoindazole and a Vitamin D analog, or
pharmaceutically acceptable salts thereof is administered
substantially simultaneously as the second agent. By "substantially
simultaneously," it is meant that the compound selected from
idebenone, benazepril, rolipram, moxonidine, lamivudine,
loxoprofen, terbinafine, synephrine, 6-aminoindazole and a Vitamin
D analog, or pharmaceutically acceptable salts thereof is
administered before, at the same time, and/or after the
administration of the second agent. Second agents include, for
example, anti-inflammatory agents, anti-cancer agents,
anti-infective agents, immune therapeutics (immunosuppresants) and
other therapeutic compounds. A second agent can be chosen based on
the condition or disease to be treated. For example, in a method of
treating cancer or a tumor, the compound selected from idebenone,
benazepril, rolipram, moxonidine, lamivudine, loxoprofen,
terbinafine, synephrine, 6-aminoindazole, and a Vitamin D analog,
or pharmaceutically acceptable salts thereof can be administered
with an anti-cancer agent. Similarly, in a method of treating an
inflammatory condition, the compound selected from idebenone,
benazepril, rolipram, moxonidine, lamivudine, loxoprofen,
terbinafine, synephrine, 6-aminoindazole and a Vitamin D analog, or
pharmaceutically acceptable salts thereof can be administered with
an anti-inflammatory agent, an anti-infective agent or an
immunosuppressant.
[0073] An anti-infective agent is an agent which reduces the
activity of or kills a microorganism and includes: Aztreonam;
Chlorhexidine Gluconate; Imidurea; Lycetamine; Nibroxane;
Pirazmonam Sodium; Propionic Acid; Pyrithione Sodium; Sanguinarium
Chloride; Tigemonam Dicholine; Acedapsone; Acetosulfone Sodium;
Alamecin; Alexidine; Amdinocillin; Amdinocillin Pivoxil;
Amicycline; Amifloxacin; Amifloxacin Mesylate; Amikacin; Amikacin
Sulfate; Aminosalicylic acid; Aminosalicylate sodium; Amoxicillin;
Amphomycin; Ampicillin; Ampicillin Sodium; Apalcillin Sodium;
Apramycin; Aspartocin; Astromicin Sulfate; Avilamycin; Avoparcin;
Azithromycin; Azlocillin; Azlocillin Sodium; Bacampicillin
Hydrochloride; Bacitracin; Bacitracin Methylene Disalicylate;
Bacitracin Zinc; Bambermycins; Benzoylpas Calcium; Berythromycin;
Betamicin Sulfate; Biapenem; Biniramycin; Biphenamine
Hydrochloride; Bispyrithione Magsulfex; Butikacin; Butirosin
Sulfate; Capreomycin Sulfate; Carbadox; Carbenicillin Disodium;
Carbenicillin Indanyl Sodium; Carbenicillin Phenyl Sodium;
Carbenicillin Potassium; Carumonam Sodium; Cefaclor; Cefadroxil;
Cefamandole; Cefamandole Nafate; Cefamandole Sodium; Cefaparole;
Cefatrizine; Cefazaflur Sodium; Cefazolin; Cefazolin Sodium;
Cefbuperazone; Cefdinir; Cefepime; Cefepime Hydrochloride;
Cefetecol; Cefixime; Cefinenoxime Hydrochloride; Cefmetazole;
Cefinetazole Sodium; Cefonicid Monosodium; Cefonicid Sodium;
Cefoperazone Sodium; Ceforanide; Cefotaxime Sodium; Cefotetan;
Cefotetan Disodium; Cefotiam Hydrochloride; Cefoxitin; Cefoxitin
Sodium; Cefpimizole; Cefpimizole Sodium; Cefpiramide; Cefpiramide
Sodium; Cefpirome Sulfate; Cefpodoxime Proxetil; Cefprozil;
Cefroxadine; Cefsulodin Sodium; Ceftazidime; Ceftibuten;
Ceftizoxime Sodium; Ceftriaxone Sodium; Cefuroxime; Cefuroxime
Axetil; Cefuroxime Pivoxetil; Cefuroxime Sodium; Cephacetrile
Sodium; Cephalexin; Cephalexin Hydrochloride, Cephaloglycin;
Cephaloridine; Cephalothin Sodium; Cephapirin Sodium; Cephradine;
Cetocycline Hydrochloride; Cetophenicol; Chloramphenicol;
Chloramphenicol Palmitate; Chloramphenicol Pantothenate Complex;
Chloramphenicol Sodium Succinate; Chlorhexidine Phosphanilate;
Chloroxylenol; Chlortetracycline Bisulfate; Chlortetracycline
Hydrochloride; Cinoxacin; Ciprofloxacin; Ciprofloxacin
Hydrochloride; Cirolemycin; Clarithromycin; Clinafloxacin
Hydrochloride; Clindamycin; Clindamycin Hydrochloride; Clindamycin
Palmitate Hydrochloride; Clindamycin Phosphate; Clofazimine;
Cloxacillin Benzathine; Cloxacillin Sodium; Cloxyquin;
Colistimethate Sodium; Colistin Sulfate; Coumermycin; Coumermycin
Sodium; Cyclacillin; Cycloserine; Dalfopristin; Dapsone;
Daptomycin; Demeclocycline; Demeclocycline Hydrochloride;
Demecycline; Denofungin; Diaveridine; Dicloxacillin; Dicloxacillin
Sodium; Dihydrostreptomycin Sulfate; Dipyrithione; Dirithromycin;
Doxycycline; Doxycycline Calcium; Doxycycline Fosfatex; Doxycycline
Hyclate; Droxacin Sodium; Enoxacin; Epicillin; Epitetracycline
Hydrochloride; Erythromycin; Erythromycin Acistrate; Erythromycin
Estolate; Erythromycin Ethylsuccinate; Erythromycin Gluceptate;
Erythromycin Lactobionate; Erythromycin Propionate; Erythromycin
Stearate; Ethambutol Hydrochloride; Ethionamide; Fleroxacin;
Floxacillin; Fludalanine; Flumequine; Fosfomycin; Fosfomycin
Tromethamine; Fumoxicillin; Furazolium Chloride; Furazolium
Tartrate; Fusidate Sodium; Fusidic Acid; Gentamicin Sulfate;
Gloximonam; Gramicidin; Haloprogin; Hetacillin; Hetacillin
Potassium; Hexedine; Ibafloxacin; Imipenem; Isoconazole;
Isepamicin; Isoniazid; Josamycin; Kanamycin Sulfate; Kitasamycin;
Levofuraltadone; Levopropylcillin Potassium; Lexithromycin;
Lincomycin; Lincomycin Hydrochloride; Lomefloxacin; Lomefloxacin
Hydrochloride; Lomefloxacin Mesylate; Loracarbef; Mafenide;
Meclocycline; Meclocycline Sulfosalicylate; Megalomicin Potassium
Phosphate; Mequidox; Meropenem; Methacycline; Methacycline
Hydrochloride; Methenamine; Methenamine Hippurate; Methenamine
Mandelate; Methicillin Sodium; Metioprim; Metronidazole
Hydrochloride; Metronidazole Phosphate; Mezlocillin; Mezlocillin
Sodium; Minocycline; Minocycline Hydrochloride; Mirincamycin
lydrochloride; Monensin; Monensin Sodium; Nafcillin Sodium;
Nalidixate Sodium; Nalidixic Acid; Natamycin; Nebramycin; Neomycin
Palmitate; Neomycin Sulfate; Neomycin Undecylenate; Netilmicin
Sulfate; Neutramycin; Nifuradene; Nifuraldezone; Nifuratel;
Nifuratrone; Nifurdazil; Nifurimide; Nifurpirinol; Nifurquinazol;
Nifurthiazole; Nitrocycline; Nitrofurantoin; Nitromide;
Norfloxacin; Novobiocin Sodium; Ofloxacin; Ormetoprim; Oxacillin
Sodium; Oximonam; Oximonam Sodium; Oxolinic Acid; Oxytetracycline;
Oxytetracycline Calcium; Oxytetracycline Hydrochloride; Paldimycin;
Parachlorophenol; Paulomycin; Pefloxacin; Pefloxacin Mesylate;
Penamecillin; Penicillin G Benzathine; Penicillin G Potassium;
Penicillin G Procaine; Penicillin G Sodium; Penicillin V;
Penicillin V Benzathine; Penicillin V Hydrabamine; Penicillin V
Potassium; Pentizidone Sodium; Phenyl Aminosalicylate; Piperacillin
Sodium; Pirbenicillin Sodium; Piridicillin Sodium; Pirlimycin
Hydrochloride; Pivampicillin Hydrochloride; Pivampicillin Pamoate;
Pivampicillin Probenate; Polymyxin B Sulfate; Porfiromycin;
Propikacin; Pyrazinamide; Pyrithione Zinc; Quindecamine Acetate;
Quinupristin; Racephenicol; Ramoplanin; Ranimycin; Relomycin;
Repromicin; Rifabutin; Rifametane; Rifamexil; Rifamide; Rifampin;
Rifapentine; Rifaximin; Rolitetracycline; Rolitetracycline Nitrate;
Rosaramicin; Rosaramicin Butyrate; Rosaramicin Propionate;
Rosaramicin Sodium Phosphate; Rosaramicin Stearate; Rosoxacil;
Roxarsone; Roxithromycin; Sancycline; Sanfetrinem Sodium;
Sarmoxicillin; Sarpicillin; Scopafungin; Sisomicin; Sisomicin
Sulfate; Sparfloxacin; Spectinomycin Hydrochloride; Spiramycin;
Stallimycin Hydrochloride; Steffimycin; Streptomycin Sulfate;
Streptonicozid; Sulfabenz: Sulfabenzamide; Sulfacetamide;
Sulfacetamide Sodium; Sulfacytine; Sulfadiazine; Sulfadiazine
Sodium; Sulfadoxine; Sulfalene; Sulfamerazine; Sulfameter:
Sulfamethazine; Sulfamethizole; Sulfamethoxazole;
Sulfamonomethoxine; Sulfamoxole; Sulfanilate Zinc; Sulfanitran;
Sulfasalazine; Sulfasomizole; Sulfathiazole; Sulfazamet;
Sulfisoxazole; Sulfisoxazole Acetyl; Sulfisoxazole Diolamine;
Sulfomyxin; Sulopenem; Sultamicillin; Suncillin Sodium;
Talampicillin Hydrochloride; Teicoplanin; Temafloxacin
Hydrochloride; Temocillin; Tetracycline; Tetracycline
Hydrochloride; Tetracycline Phosphate Complex; Tetroxoprim;
Thiamphenicol; Thiphencillin Potassium; Ticarcillin Cresyl Sodium:
Ticarcillin Disodium; Ticarcillin Monosodium; Ticlatone; Tiodonium
Chloride; Tobramycin; Tobramycin Sulfate; Tosufloxacin;
Trimethoprim; Trimethoprim Sulfate; Trisulfapyrimidines;
Troleandomycin; Trospectomycin Sulfate; Tyrothricin; Vancomycin;
Vancomycin Hydrochloride; Virginiamycin; Zorbamycin; Difloxacin
Hydrochloride; Lauryl Isoquinolinium Bromide; Moxalactam Disodium;
Ornidazole; Pentisomicin; and Sarafloxacin Hydrochloride.
[0074] Exemplary anti-cancer agents include Acivicin; Aclarubicin;
Acodazole
[0075] Hydrochloride; Acronine; Adozelesin; Aldesleukin;
Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide;
Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin;
Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa;
Bicalutamide; Bisantrene Hydrochloride; Bisnafide Dimesylate;
Bizelesin; Bleomycin Sulfate; Brequinar Sodium; Bropirimine;
Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer;
Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin;
Cedefingol; Chlorambucil; Cirolemycin; Cisplatin; Cladribine;
Crisnatol Mesylate; Cyclophosphamide; Cytarabine; Dacarbazine;
Dactinomycin; Daunorubicin Hydrochloride; Decitabine;
Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; Diaziquone;
Docetaxel; Doxorubicin; Doxorubicin Hydrochloride; Droloxifene;
Droloxifene Citrate; Dromostanolone Propionate; Duazomycin;
Edatrexatc; Eflorithine Hydrochloride; Elsamitrucin; Enloplatin;
Enpromate; Epipropidine; Epirubicin Hydrochloride; Erbulozole;
Esorubicin Hydrochloride; Estramustine; Estramustine Phosphate
Sodium; Etanidazole; Etoposide; Etoposide Phosphate; Etoprine;
Fadrozole Hydrochloride; Fazarabine; Fenretinide; Floxuridine;
Fludarabine Phosphate; Fluorouracil; Fluorocitabine; Fosquidone;
Fostriecin Sodium; Gemcitabine; Gemcitabine Hydrochloride;
Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofosine;
Interferon Alfa-2a; Interferon Alfa-2b; Interferon Alfa-n1;
Interferon Alfa-n3; Interferon Beta-I a; Interferon Gamma-I b;
Iproplatini; Irinotecan Hydrochloride; Lanreotide Acetate;
Letrozole; Leuprolide Acetate; Liarozole Hydrochloride; Lometrexol
Sodium; Lomustine; Losoxantrone Hydrochloride; Masoprocol;
Maytansine; Mechlorethamine Hydrochloride; Megestrol Acetate;
Melengestrol Acetate; Melphalan; Menogaril; Mercaptopurine;
Methotrexate; Methotrexate Sodium; Metoprine; Meturedepa;
Mitindomide; Mitocarcin; Mitocromin; Mitogillin; Mitomalcin;
Mitomycin; Mitosper; Mitotane; Mitoxantrone Hydrochloride;
Mycophenolic Acid; Nocodazole; Nogalamycin; Ormaplatin; Oxisuran;
Paclitaxel; Pegaspargase; Peliomycin; Pentamustine; Peplomycin
Sulfate; Perfosfamide; Pipobroman; Piposulfan; Piroxantrone
Hydrochloride; Plicamycin; Plomestane; Podofilox; Porfimer Sodium;
Porfiromycin; Prednimustine; Procarbazine Hydrochloride; Puromycin;
Puromycin Hydrochloride; Pyrazofurin; Riboprine; Rogletimide;
Safingol; Safingol Hydrochloride; Semustine; Simtrazene; Sparfosate
Sodium; Sparsomycin; Spirogermanium Hydrochloride; Spiromustine;
Spiroplatin; Streptonigrin; Streptozocin; Sulofenur; Talisomycin;
Taxotere; Tecogalan Sodium; Tegafur, Teloxantrone Hydrochloride;
Temoporfin; Teniposide; Teroxirone; Testolactone; Thiamiprine;
Thioguanine; Thiotepa; Tiazofurin; Tirapazamine; Topotecan
Hydrochloride; Toremifene Citrate; Trestolone Acetate; Triciribine
Phosphate; Trimetrexate; Trimetrexate Glucuronate; Triptorelin;
Tubulozole Hydrochloride; Uracil Mustard; Uredepa; Vapreotide;
Verteporlin; Vinblastine Sulfate; Vincristine Sulfate; Vindesine;
Vindesine Sulfate; Vinepidine Sulfate; Vinglycinate Sulfate;
Vinleurosine Sulfate; Vinorelbine Tartrate Virlrosidine Sulfate;
Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin; and
Zorubicin Hydrochloride.
[0076] Exemplary immunosuppressants include Azathioprine;
Azathioprine Sodium; Cyclosporine; Daltroban; Gusperimus
Trihydrochloride; Sirolimus; and Tacrolimus.
[0077] Exemplary anti-inflammatory agents include Alclofenac;
Alclometasone Dipropionate; Algestone Acetonide; Alpha Amylase;
Amcinafal; Amcinafide; Amfenac Sodium; Amiprilose Hydrochloride;
Anakinra; Anirolac; Anitrazafen; Apazone; Balsalazide Disodium;
Bendazac; Benoxaprofen; Benzydamine Hydrochloride; Bromelains;
Broperamole; Budesonide; Carprofen; Cicloprofen; Cintazone;
Cliprofen; Clobetasol Propionate; Clobetasone Butyrate; Clopirac;
Cloticasone Propionate; Cormethasone Acetate; Cortodoxone;
Deflazacort; Desonide; Desoximetasone; Dexamethasone Dipropionate;
Diclofenac Potassium; Diclofenac Sodium; Diflorasone Diacetate;
Diflumidone Sodium; Diflunisal; Difluprednate; Diftalone; Dimethyl
Sulfoxide; Drocinonide; Endrysone; Enlimomab; Enolicam Sodium;
Epirizole; Etodolac; Etofenamate; Felbinac; Fenamole; Fenbufen;
Fenclofenac; Fenclorac; Fendosal; Fenpipalone; Fentiazac;
Flazalone; Fluazacort; Flufenamic Acid; Flumizole; Flunisolide
Acetate; Flunixin; Flunixin Meglumine; Fluocortin Butyl;
Fluorometholone Acetate; Fluquazone; Flurbiprofen; Fluretofen;
Fluticasone Propionate; Furaprofen; Furobufen; Halcinonide;
Halobetasol Propionate; Halopredone Acetate; Ibufenac; Ibuprofen;
Ibuprofen Aluminum; Ibuprofen Piconol; Ilonidap; Indomethacin;
Indomethacin Sodium; Indoprofen; Indoxole; Intrazole; Isoflupredone
Acetate; Isoxepac; Isoxicam; Ketoprofen; Lofemizole Hydrochloride;
Lornoxicam; Loteprednol Etabonate; Meclofenamate Sodium;
Meclofenamic Acid; Meclorisone Dibutyrate; Mefenamic Acid;
Mesalamine; Meseclazone; Methylprednisolone Suleptanate;
Morniflumate; Nabumetone; Naproxen; Naproxen Sodium; Naproxol;
Nimazone; Olsalazine Sodium; Orgotein; Orpanoxin; Oxaprozin;
Oxyphenbutazone; Paranyline Hydrochloride; Pentosan Polysulfate
Sodium; Phenbutazone Sodium Glycerate; Pirfenidone; Piroxicam;
Piroxicam Cinnamate; Piroxicam Olamine; Pirprofen; Prednazate;
Prifelone; Prodolic Acid; Proquazone; Proxazole; Proxazole Citrate;
Rimexolone; Romazarit; Salcolex; Salnacedin; Salsalate;
Sanguinarium Chloride; Seclazone; Sermetacin; Sudoxicam; Sulindac;
Suprofen; Talmetacin; Talniflumate; Talosalate; Tebufelone;
Tenidap; Tenidap Sodium; Tenoxicam; Tesicam; Tesimide; Tetrydamine;
Tiopinac; Tixocortol Pivalate; Tolmetin; Tolmetin Sodium;
Triclonide; Triflumidate; Zidometacin; and Zomepirac Sodium.
[0078] As used herein, "treatment" and/or "treating" refer to
therapeutic treatment as well as prophylactic treatment or
preventative measures. A compound selected from the group
consisting of idebenone, benazepril, rolipram, moxonidine,
lamivudine, loxoprofen, terbinafine, synephrine, 6-aminoindazole,
and a Vitamin D analog, or pharmaceutically acceptable salts
thereof can be administered in pharmaceutical compositions
comprising a pharmaceutically acceptable carrier or excipient. The
excipient can be chosen based on the expected route of
administration of the composition in therapeutic applications. The
route of administration of the composition depends on the condition
to be treated. For example, intravenous injection may be preferred
for treatment of a systemic disorder and oral administration may be
preferred to treat a gastrointestinal disorder. The route of
administration and the dosage of the composition to be administered
can be determined by the skilled artisan without undue
experimentation in conjunction with standard dose-response studies.
Relevant circumstances to be considered in making those
determinations include the condition or conditions to be treated,
the choice of composition to be administered, the age, weight, and
response of the individual patient, and the severity of the
patient's symptoms.
[0079] Pharmaceutical compositions comprising the compounds
described above can be administered by a variety of routes
including, but not limited to, parenteral, oral, pulmonary,
ophthalmic, nasal, rectal, vaginal, aural, topical, buccal,
transdermal, intravenous, intramuscular, subcutaneous, intradermal,
intraocular, intracerebral, intralymphatic, intraarticular,
intrathecal and intraperitoneal.
[0080] In one embodiment, the pharmaceutical composition can be
administered orally. For the purpose of oral therapeutic
administration, the pharmaceutical compositions can be incorporated
with excipients and used in the form of tablets, troches, capsules,
elixirs, suspensions, syrups, wafers, chewing gums and the like.
Tablets, pills, capsules, troches and the like may also contain
binders, excipients, disintegrating agent, lubricants, glidants,
sweetening agents, and flavoring agents. Some examples of binders
include microcrystalline cellulose, gum tragacanth or gelatin.
Examples of excipients include starch or lactose. Some examples of
disintegrating agents include alginic acid, corn starch and the
like. Examples of lubricants include magnesium stearate or
potassium stearate. An example of a glidant is colloidal silicon
dioxide. Some examples of sweetening agents include sucrose,
saccharin and the like. Examples of flavoring agents include
peppermint, methyl salicylate, orange flavoring and the like.
Materials used in preparing these various compositions should be
pharmaceutically pure and non-toxic in the amounts used. In another
embodiment, the composition is administered as a tablet or a
capsule.
[0081] Various other materials may be present as coatings or to
modify the physical form of the dosage unit. For instance, tablets
may be coated with shellac, sugar or both. A syrup or elixir may
contain, in addition to the active ingredient, sucrose as a
sweetening agent, methyl and propylparabens as preservatives, a dye
and a flavoring such as cherry or orange flavor, and the like. For
vaginal administration, a pharmaceutical composition may be
presented as pessaries, tampons, creams, gels, pastes, foams or
spray.
[0082] The pharmaceutical composition can also be administered by
nasal administration. As used herein, nasally administering or
nasal administration includes administering the composition to the
mucus membranes of the nasal passage or nasal cavity of the
patient. As used herein, pharmaceutical compositions for nasal
administration of a composition include therapeutically effective
amounts of the compounds prepared by well-known methods to be
administered, for example, as a nasal spray, nasal drop,
suspension, gel, ointment, cream or powder. Administration of the
composition may also take place using a nasal tampon or nasal
sponge.
[0083] For topical administration, suitable formulations may
include biocompatible oil, wax, gel, powder, polymer, or other
liquid or solid carriers. Such formulations may be administered by
applying directly to affected tissues, for example, a liquid
formulation to treat infection of conjunctival tissue can be
administered dropwise to the subject's eye, or a cream formulation
can be administered to the skin.
[0084] The compositions can be administered parenterally such as,
for example, by intravenous, intramuscular, intrathecal or
subcutaneous injection. Parenteral administration can be
accomplished by incorporating a composition into a solution or
suspension. Such solutions or suspensions may also include sterile
diluents such as water for injection, saline solution, fixed oils,
polyethylene glycols, glycerine, propylene glycol or other
synthetic solvents. Parenteral formulations may also include
antibacterial agents such as, for example, benzyl alcohol or methyl
parabens, antioxidants such as, for example, ascorbic acid or
sodium bisulfite and chelating agents such as EDTA. Buffers such as
acetates, citrates or phosphates and agents for the adjustment of
tonicity such as sodium chloride or dextrose may also be added. The
parenteral preparation can be enclosed in ampules, disposable
syringes or multiple dose vials made of glass or plastic.
[0085] Rectal administration includes administering the
pharmaceutical compositions into the rectum or large intestine.
This can be accomplished using suppositories or enemas. Suppository
formulations can easily be made by methods known in the art. For
example, suppository formulations can be prepared by heating
glycerin to about 120.degree. C., dissolving the pharmaceutical
composition in the glycerin, mixing the heated glycerin after which
purified water may be added, and pouring the hot mixture into a
suppository mold.
[0086] Transdermal administration includes percutaneous absorption
of the composition through the skin. Transdermal formulations
include patches, ointments, creams, gels, salves and the like.
[0087] In addition to the usual meaning of administering the
formulations described herein to any part, tissue or organ whose
primary function is gas exchange with the external environment, for
purposes of the present invention, "pulmonary" will also mean to
include a tissue or cavity that is contingent to the respiratory
tract, in particular, the sinuses. For pulmonary administration, an
aerosol formulation containing the active agent, a manual pump
spray, nebulizer or pressurized metered-dose inhaler as well as dry
powder formulations are contemplated. Suitable formulations of this
type can also include other agents, such as antistatic agents, to
maintain the disclosed compounds as effective aerosols.
[0088] A drug delivery device for delivering aerosols comprises a
suitable aerosol canister with a metering valve containing a
pharmaceutical aerosol formulation as described and an actuator
housing adapted to hold the canister and allow for drug delivery.
The canister in the drug delivery device has a head space
representing greater than about 15% of the total volume of the
canister. Often, the compound intended for pulmonary administration
is dissolved, suspended or emulsified in a mixture of a solvent,
surfactant and propellant. The mixture is maintained under pressure
in a canister that has been sealed with a metering valve.
[0089] The invention is illustrated by the following examples which
are not meant to be limiting in any way.
EXEMPLIFICATION
Example 1
Method of Determining Chemorepulsive and Chemoattractive
Activity
[0090] The chemorepulsive activity of idebenone, benazepril,
rolipram, moxonidine, lamivudine, calcitriol, calcipotriol,
loxoprofen, terbinafine, synephrine and 6-aminoindazole was
determined as follows: [0091] 1. Prior to beginning the assay, the
following were prepared: [0092] a. 0.5% Fetal Calf Serum (FCS) in
Iscove's Modified Dulbecco's Medium (IMDM) (Assay Medium) (Both
from ATCC). [0093] b. Migratory cells at a concentration of
2.times.10.sup.7 cells/ml in Assay Medium. [0094] c. The indicated
dilutions of the ligand of interest in Assay Medium were prepared.
[0095] 2. The assay plates are Neuroprobe ChemoTx plates, part
number 206-3 (3 um pore size) for neutrophils. [0096] 3. The plates
were removed from packaging, leaving the membrane behind. [0097] 4.
31 .mu.l of the following solutions were pipetted into each well:
[0098] a. For media controls and for chemorepulsion samples, Assay
Medium was used. [0099] b. For chemoattraction samples, appropriate
dilution of ligand was used. [0100] 5. A sterile needle was used to
pop any and all small bubbles present in each well. [0101] 6. The
membrane was carefully placed onto the plate, starting at one side
and then slowly lowering the other edge onto the plate. [0102] 7.
29 .mu.l of the following were pipetted onto the top of each
circle: [0103] a. For media controls and chemoattraction (CA)
samples, use Assay Medium. [0104] b. For chemorepulsion (CR)
samples, use the appropriate dilution of ligand. [0105] 8. 2 .mu.A
of cells (40,000 cells) were added to each bubble of liquid from
step 7. [0106] 9. A needle was used to pop all air bubbles. [0107]
10. The plate was covered with the supplied lid and incubated for
the desired time at 37.degree. C. in 5% CO.sub.2. Unless otherwise
indicated, the incubation time was 1 hour for neutrophils and 3
hours for T cells. For monocytes and B cells, the incubation time
was 2 hours. [0108] 11. After the desired assay time, the liquid
was removed from the top of the plate using a Kimwipe. At this
point, the plate was stored (with the membrane in place) for up to
2 hours at 4.degree. C. [0109] 12. The membrane was carefully
removed from the top of the plate and discard. The plate was
examined under a microscope to look for ligand crystallization,
contamination and overall migration. [0110] 13. White read plates
were preloaded with 25 ul PBS. [0111] 14. Using a multichannel
pipettor, 5 ul of Cell Titer Glo (Promega #G7572) was added to each
well. [0112] 15. Using a multichannel pipettor set at 30 ul, lysed
cell solution was transferred to white read plates pre-loaded with
PBS. [0113] 16. The plate was read using the BioTek Synergy4 plate
reader in order to quantify the number of migrated cells.
[0114] Idebenone, benazepril, rolipram, moxonidine, lamivudine,
calcitriol, loxoprofen, terbinafine, synephrine and
6-aminoindazoleshowed chemorepulsion in at least two replicates
that was greater than 2-fold over media.
[0115] FIGS. 1A-C shows that neutrophils treated with 102 uM
idebenone showed greater than 7-fold induction of chemorepulsion as
compared to neutrophils treated with media.
[0116] FIGS. 2A, B and C shows replicates in which neutrophils
treated with 0.92 uM benazepril showed about 2-fold greater
induction of chemorepulsion over media.
[0117] FIGS. 3A and B shows replicates in which neutrophils treated
with 0.1 uM rolipram showed 2-fold greater induction of
chemorepulsion than those treated with media.
[0118] FIGS. 4A and 4B shows replicates in which neutrophils
treated with 0.092 uM moxonidine hydrochloride showed about 2-fold
greater induction of chemorepulsion than neutrophils treated with
media.
[0119] FIGS. 5A and 5B shows replicates in which neutrophils
treated with 9.9 uM moxonidine showed greater than 2-fold induction
of chemorepulsion than neutrophils treated with media.
[0120] FIGS. 6A-C shows that neutrophils treated with 100 uM
calcitriol showed greater than 3-fold induction of chemorepulsion
than neutrophils treated with media.
[0121] FIGS. 7A-C shows that neutrophils treated with 89 uM
terbinafine hydrochloride showed greater than 2.5 fold induction of
chemorepulsion than neutrophils treated with media.
[0122] FIGS. 8A and B shows replicates in which neutrophils treated
with 0.1 uM synephrine showed greater than 2-fold induction of
chemorepulsion than neutrophils treated with media.
[0123] FIGS. 9A and B shows replicates in which neutrophils treated
with 0.1 uM 6-aminoindazole showed greater than 3-fold induction of
chemorepulsion than neutrophils treated with media.
[0124] FIGS. 10A and B shows replicates in which neutrophils
treated with 0.091 uM loxoprofen sodium showed greater than 2-fold
induction of chemorepulsion than neutrophils treated with
media.
Example 2
Calcitriol Analogs
[0125] The calcitriol analogs listed below were screened at
concentrations of 3.7, 11.1, 33.3 and 100 uM as described above for
chemorepulsive activity (FIGS. 11-13). FIG. 14 shows the
chemorepulsive activity of calcipotriol at 0.101, 1.01, 10.1 and
100.1 uM,
[0126] The activity of the Vitamin D analogs is shown below in
Table 1.
TABLE-US-00001 TABLE 1 Molecular Compound Weight Activity
Calcipotriene 412.6 Chemorepellant Vitamin D2 396.7 Chemorepellant
Vitamin D3 384.6 Chemorepellant 1.alpha.-hydroxycholecalciferol
400.6 No activity (1.alpha.-OH-D3) 1.alpha.-hydroxyvitamin D2
(1.alpha. 412.7 No activity OH-D2) Calcefidiol 400.6 No
activity
[0127] While this invention has been particularly shown and
described with references to preferred embodiments thereof, it will
be understood by those skilled in the art that various changes in
form and details may be made therein without departing from the
scope of the invention encompassed by the appended claims.
* * * * *